I-Remdesivir liyeza le-antiviral elijolise kuluhlu lweentsholongwane. Yaphuhliswa ekuqaleni kwisithuba seminyaka elishumi edlulileyo ukunyanga i-hepatitis C kunye nentsholongwane efana nebandayo ebizwa ngokuba yi-respiratory syncytial virus (RSV). I-Remdesivir ibingelonyango olusebenzayo kuso nasiphi na isifo. Kodwa yabonisa isithembiso ngokuchasene nezinye iintsholongwane.

Abaphandi bavavanya i-remdesivir kulingo lwezonyango ngexesha lokuqhambuka kwe-Ebola. Amanye amayeza ophando asebenze ngcono, kodwa kwaboniswa ukuba akhuselekile kwizigulana. Uphononongo kwiiseli kunye nezilwanyana lucebise ukuba i-remdesivir yayisebenza ngokuchasene neentsholongwane kusapho lwe-coronavirus, ezinje ngeMiddle East Respiratory Syndrome (MERS) kunye neSevere Acute Respiratory Syndrome (SARS).

I-Remdesivir isebenza ngokuphazamisa ukuveliswa kwentsholongwane. IiCoronavirus zineejenomes ezenziwe yi-ribonucleic acid (RNA). I-Remdesivir iphazamisana nenye yee-enzymes eziphambili ezifunwa yintsholongwane ukuphindaphinda i-RNA. Oku kuthintela intsholongwane ekuphindaphindeni.

Abaphandi baqala ulingo olungahleliwe, olulawulwayo lwe-antiviral ngoFebruwari ka-2020 ukuvavanya ukuba i-remdesivir ingasetyenziselwa ukunyanga i-SARS-CoV-2, i-coronavirus ebangela i-COVID-19. NgoAprili,iziphumo zakwangokoibonise ukuba i-remdesivir ikhawulezise ukuchacha kwezigulana ezisesibhedlele ezine-COVID-19 eqatha. Yaba lichiza lokuqala ukufumana ugunyaziso losetyenziso olungxamisekileyo kwi-US Food and Drug Administration (FDA) ukunyanga abantu abalaliswe esibhedlele nge-COVID-19.

Abaphandi ngoku balugqibile ulingo, olwaziwa njenge-Adaptive COVID-19 Treatment Trial (ACTT-1). Uphononongo lwaxhaswa ngemali liZiko leSizwe leZifo zoKwalisa kunye neZifo ezosulelayo (NIAID). Ingxelo yokugqibela yavela kwiNew England Journal of Medicinengo-Okthobha 8, 2020.